New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 23, 2014
09:20 EDTINOInovio's VGX-3100 for cervical dysplasia shows positive Phase II results
Inovio Pharmaceuticals announced successful results from its randomized, double-blind, placebo-controlled phase II trial of VGX-3100 in women with biopsy-proven cervical intraepithelial neoplasia 2/3 associated with human papillomavirus types 16 or 18. Treatment with VGX-3100 resulted in histopathological regression of CIN2/3 to CIN1 or no disease, meeting the study's primary endpoint. The trial demonstrated clearance of HPV in conjunction with regression of cervical lesions. Robust T-cell activity was detected in subjects who received VGX-3100 compared to those who received placebo.
News For INO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 1, 2014
08:01 EDTINOInovio volatility low into CDC confirms first U.S. Ebola case in Texas
Inovio overall option implied volatility of 57 compares to its 26-week average of 102 according to Track Data, suggesting decreasing price movement into CDC confirms the first U.S. Ebola case in Texas.
September 26, 2014
07:32 EDTINOBioCentury to hold a conference
21st Annual NewsMakers in the Biotech Industry Conference to be held in New York on September 26.
September 24, 2014
06:02 EDTINOInovio Ebola vaccine moving into human trial with GeneOne Life Science
Subscribe for More Information
September 22, 2014
08:10 EDTINOInovio initiates phase I clinical trial in patients with aerodigestive cancers
Inovio announced it has initiated a phase I clinical trial in patients with aerodigestive cancers. The trial will evaluate the safety, tolerability, and immunogenicity of INO-3106. This immunotherapy targets human papillomavirus type 6, which causes most aerodigestive cancers. This study is part of Inovio's strategy to broadly expand clinical development of its DNA-based immune therapy products to treat different HPV types and the many diseases they cause. It is a phase I, open label compassionate study enrolling patients with invasive cancer who have exhausted all other treatment options. The study will test Inovio's immunotherapy, INO-3106, alone or in combination with DNA-based IL-12, Inovio's proprietary immune activator, in subjects with HPV-6 associated aerodigestive malignancies. Successful results could open a path to pursuing an FDA orphan designation for aerodigestive cancers.
September 19, 2014
10:53 EDTINO Options with increasing implied volatility: ESI INO VALE AGNC
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use